Bioperfectus Obtains CE Mark for SARS-CoV-2 Antigen Rapid Self-Test
By LabMedica International staff writers Posted on 05 Jan 2022 |
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) has obtained CE Mark for its Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).
The lateral flow test is intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. It delivers fast results within 15 minutes and is able to detect asymptomatic cases as well as remain effective in the case of variants.
The Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in the German and Austrian markets since May 20th, 2021. With the CE Mark, the test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants